Conclusion
Through this case, we demonstrate the importance of involving multidisciplinary team in decision making, as balancing maternal complications as well as reassuring fetal wellbeing during such critical period is imperative. We have thus confirmed the feasibility of using convalescent plasma and ECMO during early postnatal period in critically ill obstetric patients with respiratory failure. The use of tocilizumab, convalescent plasma, followed by intensive care management with intubation and ECMO might have potentially contributed to the complete recovery of the mother and the newborn. Whether antimalarials-hydroxychloroquine (in particular), and/or antivirals are effective in treating COVID-19 - remains unknown. Further well-defined studies are necessary to study the effectiveness and safety of plasma transfusion in COVID-19 patients.